Company intelligence / Profile preview

ONE2ZEE

Rotterdam, South Holland, Netherlands

Ownership: Private
Development stage: Other

Overview

One2Zee is a Dutch biotechnology company focused on developing transformative therapies for rare neurodevelopmental disorders, with a primary focus on Angelman syndrome. The company's approach centers on identifying and modulating specific protein-protein interactions that are critical to neuronal function and development. By leveraging deep expertise in the molecular mechanisms of the brain, One2Zee aims to restore normal cellular processes in patients with severe genetic conditions. Their lead programs are currently in the pre-clinical stage, targeting the underlying causes of synaptic dysfunction.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Erasmus University Medical Center

Beyond the preview

Go deeper on ONE2ZEE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONE2ZEE.

Explore the full profile